Matthew Gavidia

October 01, 2022

Patients with alopecia areata showed improved response rate with oral Janus kinase (JAK) inhibitors vs topical and sublingual JAK inhibitor administration.

September 30, 2022

A panel discussion at the 70th Annual Roy A. Bowers Pharmaceutical Conference addressed recent care delivery initiatives in New Jersey that aim to address health inequities and other population health concerns.

September 30, 2022

Melissa O'Connor, PhD, MBA, RN, FGSA, FAAN, endowed professor in Community and Home Health Nursing, M. Louise Fitzpatrick School of Nursing, Villanova University, and director, Gerontology Interest Group, discussed several factors for clinicians to consider in creating plans to discharge adults from skilled home health care.

September 28, 2022

An FDA advisory committee recently issued a positive vote for Ferring’s RBX2660, an investigational microbiota-based live biotherapeutic, for its potential in reducing recurrent Clostridioides difficile infection after antibiotic treatment.

September 28, 2022

Adherence to 8-week square-stepping exercise training among patients with Parkinson disease was associated with significant improvement of executive functioning, as well as cognitive functioning for those with mild cognitive impairment.

September 27, 2022

Patients requiring maintenance hemodialysis (MHD) had a 4-fold higher risk of Clostridioides difficile infection (CDI), with rates of CDI increasing over time regardless of MHD requirement.

September 26, 2022

Significant alterations were observed in lipid levels and other skin biomarkers for infants who developed atopic dermatitis (AD) vs controls, with phytosphingosine associated with the highest AD prediction accuracy.

September 24, 2022

Tobacco smoking, depression, and increasing number of comorbidities were associated with reduced treatment satisfaction among patients with hidradenitis suppurativa.

September 24, 2022

Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, spoke on the importance of shared decision-making in deciding which biologic would best alleviate disease burden in patients with moderate to severe atopic dermatitis.

September 23, 2022

Headaches, injection site reactions, and pharyngitis were the most common adverse events associated with the biologic therapies dupilumab, omalizumab, mepolizumab, and reslizumab in the treatment of chronic rhinosinusitis (CRS) with nasal polyps.